BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 37994344)

  • 1. Wnt Signaling and Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Kishore C; Zi X
    Curr Pharmacol Rep; 2023 Oct; 9(5):261-274. PubMed ID: 37994344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt signaling in castration-resistant prostate cancer: implications for therapy.
    Yokoyama NN; Shao S; Hoang BH; Mercola D; Zi X
    Am J Clin Exp Urol; 2014 Apr; 2(1):27-44. PubMed ID: 25143959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
    Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.
    Pakula H; Xiang D; Li Z
    Cancers (Basel); 2017 Jan; 9(2):. PubMed ID: 28134791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRKAR2B promotes prostate cancer metastasis by activating Wnt/β-catenin and inducing epithelial-mesenchymal transition.
    Sha J; Han Q; Chi C; Zhu Y; Pan J; Dong B; Huang Y; Xia W; Xue W
    J Cell Biochem; 2018 Sep; 119(9):7319-7327. PubMed ID: 29761841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
    Khurana N; Sikka SC
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
    Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
    Jamroze A; Chatta G; Tang DG
    Cancer Lett; 2021 Oct; 518():1-9. PubMed ID: 34118355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer.
    Qin J; Lee HJ; Wu SP; Lin SC; Lanz RB; Creighton CJ; DeMayo FJ; Tsai SY; Tsai MJ
    J Clin Invest; 2014 Nov; 124(11):5013-26. PubMed ID: 25295534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance.
    Yeh Y; Guo Q; Connelly Z; Cheng S; Yang S; Prieto-Dominguez N; Yu X
    Adv Exp Med Biol; 2019; 1210():351-378. PubMed ID: 31900917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo.
    Liu J; Zhang R; Su T; Zhou Q; Gao L; He Z; Wang X; Zhao J; Xing Y; Sun F; Cai W; Wang X; Han J; Qin R; Désaubry L; Han B; Chen W
    J Exp Clin Cancer Res; 2023 May; 42(1):128. PubMed ID: 37210546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid hormone synthetic pathways in prostate cancer.
    Mostaghel EA
    Transl Androl Urol; 2013 Sep; 2(3):212-227. PubMed ID: 25379460
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Fararjeh AS; Liu YN
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth.
    Luo J; Wang D; Wan X; Xu Y; Lu Y; Kong Z; Li D; Gu W; Wang C; Li Y; Ji C; Gu S; Xu Y
    Onco Targets Ther; 2020; 13():9257-9267. PubMed ID: 32982312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer.
    Shore ND; Morgans AK; Ryan CJ
    Clin Genitourin Cancer; 2021 Jun; 19(3):199-207. PubMed ID: 33129718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.
    Ojo D; Lin X; Wong N; Gu Y; Tang D
    Cancers (Basel); 2015 Nov; 7(4):2290-308. PubMed ID: 26593949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
    Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
    Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.